Last reviewed · How we verify
paroxetine hydrochloride hydrate
Paroxetine selectively inhibits the reuptake of serotonin at the neuronal synapse, increasing serotonin availability in the brain.
Paroxetine selectively inhibits the reuptake of serotonin at the neuronal synapse, increasing serotonin availability in the brain. Used for Major depressive disorder, Generalized anxiety disorder, Panic disorder.
At a glance
| Generic name | paroxetine hydrochloride hydrate |
|---|---|
| Also known as | BRL29060A |
| Sponsor | GlaxoSmithKline |
| Drug class | Selective serotonin reuptake inhibitor (SSRI) |
| Target | Serotonin transporter (SERT) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Neurology |
| Phase | Phase 3 |
Mechanism of action
Paroxetine is a selective serotonin reuptake inhibitor (SSRI) that blocks the serotonin transporter protein, preventing the reabsorption of serotonin from the synaptic cleft back into presynaptic neurons. This increases serotonin concentration in the synapse, enhancing neurotransmission and improving mood regulation. The hydrochloride hydrate formulation is the salt form used for oral pharmaceutical administration.
Approved indications
- Major depressive disorder
- Generalized anxiety disorder
- Panic disorder
- Obsessive-compulsive disorder
- Post-traumatic stress disorder
- Social anxiety disorder
Common side effects
- Nausea
- Headache
- Sexual dysfunction
- Insomnia
- Somnolence
- Tremor
- Diarrhea
- Sweating
Key clinical trials
- Clinical Evaluation of BRL29060A (Paroxetine Hydrochloride Hydrate) in Posttraumatic Stress Disorder (PTSD) (PHASE2)
- Pharmacovigilance in Gerontopsychiatric Patients (PHASE3)
- BRL29060A (Paroxetine Hydrochloride Hydrate) in Posttraumatic Stress Disorder (PHASE3)
- Social Anxiety Disorder Study Of Paroxetine (PHASE3)
- Long-term Study Of Paroxetine in Women and Men (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- paroxetine hydrochloride hydrate CI brief — competitive landscape report
- paroxetine hydrochloride hydrate updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI